Evidence map›Paper›PMID 34848816›Full record

ArticleScientific reports2021

Proteomic profiling of human amnion for preterm birth biomarker discovery.

Maurizio Bruschi, Martina Bartolucci, Andrea Petretto, Francesca Buffelli, Xhuliana Kajana, Alessandro Parodi, Riccardo Carbone, Ezio Fulcheri, Luca Antonio Ramenghi, Isabella Panfoli and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Maurizio Bruschi *Laboratory of Molecular Nephrology, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini, 5, 16147, Genoa, Italy. mauriziobruschi@yahoo.it.
Martina Bartolucci *Core Facilities-Clinical Proteomics and Metabolomics, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Andrea PetrettoCore Facilities-Clinical Proteomics and Metabolomics, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Francesca BuffelliFetal-Perinatal Pathology Unit, IRCCS-Istituto Giannina Gaslini, Genoa, Italy.
Xhuliana KajanaLaboratory of Molecular Nephrology, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini, 5, 16147, Genoa, Italy.
Alessandro ParodiNeonatal Intensive Care Unit, IRCCS-Istituto Giannina Gaslini, Genoa, Italy.
Riccardo CarboneDepartment of Paediatric Science, University of Genoa, Genoa, Italy.
Ezio FulcheriFetal-Perinatal Pathology Unit, IRCCS-Istituto Giannina Gaslini, Genoa, Italy.
Luca Antonio RamenghiNeonatal Intensive Care Unit, IRCCS-Istituto Giannina Gaslini, Genoa, Italy.
Isabella PanfoliDipartimento Di Farmacia (DIFAR), Università Di Genova, Genoa, Italy.
Giovanni CandianoLaboratory of Molecular Nephrology, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini, 5, 16147, Genoa, Italy.
Istituto Giannina Gaslini · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Genoa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Spontaneous preterm birth (PTB) complicates about 12% of pregnancies worldwide, remaining the main cause of neonatal morbidity and mortality. Spontaneous preterm birth PTBs is often caused by microbial-induced preterm labor, mediated by an inflammatory process threatening both maternal and newborn health. In search for novel predictive biomarkers of PTB and preterm prelabor rupture of the membranes (pPROM), and to improve understanding of infection related PTB, we performed an untargeted mass spectrometry discovery study on 51 bioptic mid zone amnion samples from premature babies. A total of 6352 proteins were identified. Bioinformatics analyses revealed a ranked core of 159 proteins maximizing the discrimination between the selected clinical stratification groups allowing to distinguish conditions of absent (FIR 0) from maximal Fetal Inflammatory Response (FIR 3) stratified in function of Maternal Inflammatory Response (MIR) grade. Matrix metallopeptidase-9 (MMP-9) was the top differentially expressed protein. Gene Ontology enrichment analysis of the core proteins showed significant changes in the biological pathways associated to inflammation and regulation of immune and infection response. Data suggest that the conditions determining PTB would be a transversal event, secondary to the maternal inflammatory response causing a breakdown in fetal-maternal tolerance, with fetal inflammation being more severe than maternal one. We also highlight matrix metallopeptidase-9 as a potential predictive biomarker of PTB that can be assayed in the maternal serum, for future investigation.

Indexed as

AmnionBiomarkersComputational BiologyFemaleGene Expression RegulationHumansInfant, NewbornInfant, PrematureInflammationIntensive Care Units, NeonatalLeast-Squares AnalysisMass SpectrometryMatrix Metalloproteinase 9PeptidesPregnancyPremature BirthBiomarkersMatrix Metalloproteinase 9MMP9 protein, humanPeptidesProteomeTIMP1 protein, humanTissue Inhibitor of Metalloproteinase-1

Identifiers

PMID34848816
PMCPMC8633292
OpenAlexW3215236748

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.